A television advertisement for the Orexigen Therapeutics weight loss drug Contrave (naltrexone HCl and bupropion HCl) drew a warning from the FDA’s Office of Prescription Drug Promotion (OPDP), the office’s first of 2017.
Source: Drug Industry Daily